Sub navigation menu:

Products

You are here:   You are here > Products > Mirae Asset Horizons Exchange Traded Funds Series > Mirae Asset Horizons China Biotech ETF

Mirae Asset Horizons China Biotech ETF

Overview: Important information about Mirae Asset Horizons China Biotech ETF

  • Mirae Asset Horizons China Biotech ETF (the “Fund”) is an exchange traded fund and seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR (the "Underlying Index"). The Fund is an investment fund. There is no guarantee of the repayment of principal. Therefore your investment in the Fund may suffer losses.
  • Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly. In addition, the prospects of biotech companies may significantly be impacted by technological changes, increased governmental regulations and intense competition from competitors.
  • The net asset value of the Fund and its performance may be affected unfavorably by fluctuations in the exchange rates between the trading currencies, the base currency, and by changes in exchange rate controls.
  • The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investment in more developed markets, such as liquidity risk, currency risks / control, political and economic uncertainties, legal and taxation risks, settlement risks, custody risk and the likelihood of a high degree of volatility.
  • The Fund may invest in RMB denominated investments. RMB is currently not freely convertible and is subject to exchange controls and restrictions. Investors are therefore exposed to foreign exchange risk and there is no guarantee that the value of RMB will not depreciate against the investors’ base currencies (e.g. Hong Kong dollars). Any depreciation of RMB could adversely affect the value of investor’s investment in the Fund.
  • Although offshore RMB (CNH) and onshore RMB (CNY) are the same currency, they trade at different rates. Any divergence between CNH and CNY may adversely impact investors.
  • The current regulations and rules on Stock Connect are subject to change which may have potential retrospective effect. The Stock Connect is subject to quota limitations. Where a suspension in the trading through the Stock Connect is effected, the Fund’s ability to invest in A- Shares or access the PRC markets through the Stock Connect will be adversely affected. In such event, the Fund’s ability to achieve its investment objective could be negatively affected.
  • There are risks and uncertainties associated with the current PRC tax laws, regulations and practice in respect of capital gains realized via Stock Connect on the Fund’s investments in the PRC (which may have retrospective effect). Any increased tax liabilities on the Fund may adversely affect the Fund’s value.
  • Based on professional and independent tax advice, the Fund will not make any withholding corporate income tax provision on the gross released or unrealized capital gains derived from the trading of A-Shares via Stock Connect.
  • The concentration of the Fund’s investments in Chinese companies that are active in cloud computing sector may result in greater volatility in the value of the Fund than more diverse portfolios which comprise broad-based global investments, as the Fund is more susceptible to fluctuations in value of the Underlying Index resulting from adverse conditions in the PRC. The weighting of the Underlying Index is concentrated on a small number of constituents of the Underlying Index, in which case, the Underlying Index would be more easily affected by the price movements of a small number of index constituents than an index which is more broadly based.
  • The Fund is not “actively managed”, therefore when there is a decline in the Underlying Index, the Fund will also decrease in value. Mirae Asset Global Investments (Hong Kong) Limited (“the Manager”) will not adopt any temporary defensive positions against any market downturn. Investors may lose part or all of their investment.
  • Due to fees and expenses of the Fund, liquidity of the market and changes to the regulatory policies, the Fund’s return may deviate from that of the Underlying Index.
  • The trading price of the units of the fund (“Units”) on the Stock Exchange of Hong Kong Limited (“HKEx”) is driven by market factors such as the demand and supply of the Units. Therefore, the Units may trade at a substantial premium or discount to the Fund’s net asset value.
  • Payments of distributions out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the net asset value per Unit of the Fund and will reduce the capital available for future investment.
  • If there is a suspen sion of the inter-counter transfer of Units between the HKD counter and the USD counter and/or any limitation on the level of services by brokers and CCASS participants, unitholders will only be able to trade their Units in one counter only, which may inhibit or delay an investor dealing. The market price of Units traded in each counter may deviate significantly. As such, investors may pay more or receive less when buying or selling Units traded in HKD on the HKEx than in respect of Units traded in USD and vice versa.
  • Investment involves risk. Investors may lose part or all of their investment. Investors should not base on this website alone to make investment decisions. Before making any investment decision, prospective investor should read the Fund’s offering documents, which is available on this website, carefully for further details, including the product features and risk factors, and should consider seeking independent professional advice. The contents of this website is prepared and maintained by the Manager and has not been reviewed by the Securities and Futures Commission of Hong Kong (”SFC”).

 

All dollar amounts are in HKD and all dates are in GMT+8 Time, unless otherwise specified.

Fund objective and investment strategy

The Sub-Fund seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR (“Underlying Index”).

The Manager intends to adopt a full replication strategy through investing all, or substantially all, of the assets of the Sub-Fund directly in all securities constituting the Underlying Index in substantially the same weightings as these securities have in the Underlying Index to achieve the investment objective of the Sub-Fund (“Replication Strategy”).

 

Near real time Estimated NAV per Unit [1]

 
HKD USD  
$ -- $ --  
$ -- $ --  

Daily NAV per Unit [3] {{ navasofdate | madate:plocale }}

 
NAV Change Change %
Official NAV per Unit in RMB
$ {{ navperunit | number:2}} $ {{ navchange | number:2 }} {{ navpctchange | number:2 }} %
NAV per Unit in HKD [7]
$ {{ navperunit * rmbhkdfx | number:2}} $ {{ navchange * rmbhkdfx | number:2 }} {{ navpctchange | number:2 }} %
NAV per Unit in USD [7]
$ {{ navperunit * rmbusdfx | number:2}} $ {{ navchange * rmbusdfx | number:2 }} {{ navpctchange | number:2 }} %

Fund information {{ navasofdate | madate:plocale }}

Fund Inception Date
24 Jul 2019
SEHK Listing Date
25 Jul 2019
Fiscal Year
Ending 31 Mar each year
Ongoing Charges over a year [9]
0.68%
Management Fee
0.50% per annum of the NAV
Distribution Frequency
Mirae Asset Horizons China Biotech ETF aims to pay annual cash distribution (in May each year) at the Manager’s discretion.

Index information [4] {{ navasofdate | madate:plocale}}

Underlying Index
Solactive China Biotech Index NTR[8]
Base Currency
Renminbi
Closing Level
N/A
Change
N/A
Change %
N/A

Trading information {{ navasofdate | madate:plocale}}

 
HKD Traded Units [7] USD Traded Units [7]  
Exchange
Hong Kong Stock Exchange Hong Kong Stock Exchange  
Stock Code
2820 9820  
ISIN
HK0000516697 HK0000516689  
Board Lot Size
50 Units 50 Units  
Trading Currency
HKD USD  
Total Net Asset Value
{{ navtotal * rmbhkdfx | number:2 }} {{ navtotal * rmbusdfx | number:2 }}  
Outstanding Units
{{ navoutstanding }} {{ navoutstanding }}  

Participating dealers [6]

  • ABM AMRO Clearing Hong Kong Ltd
  • Haitong International Securities Company Limited
  • Mirae Asset Securities (HK) Limited

Top 10 holdings{{holdasofdate | madate:plocale}}

{{ x.weightingPercentage|number:2 }} %
{{ x.securityName }}
View all holdings
[1]
This is a near real time Estimated NAV per Unit and is indicative only. Near real time Estimated NAV per Unit in HKD / USD is calculated using the near real time Estimated NAV per Unit in RMB multiplied by the assumed foreign exchange rate as provided in note 7 below. This is provided on a 15-second delayed basis by Interactive Data Managed Solutions. (See terms and conditions) and is updated during trading hours of The Stock Exchange of Hong Kong Limited ("HKEx").
[2]
Market prices are provided on a 15-minute delayed basis by Interactive Data Managed Solutions. (See terms and conditions)
[3]
Performance is calculated on NAV to NAV. Change indicates the change since the previous business day. For more information on calculation of NAV, please refer to the Prospectus of the Fund.
[4]
Index returns are for illustrative purposes only and should not be taken as an indication or guarantee of future performance. Management fees, transaction costs or other expenses are not reflected in index returns. Change indicates the change since the closing index level of the previous business day.
[5]
Additional Market Maker(s) will be appointed from time to time.
[6]
Additional Participating Dealer(s) will be appointed from time to time.
[7]
Exchange rate of offshore RMB (CNH) to HKD as of {{rmbhkdfxdate}} is {{rmbhkdfx | number:4}}. Exchange rate of offshore RMB (CNH) to USD as of {{rmbusdfxdate}} is {{rmbusdfx | number:4}}. The exchange rate is not a real time exchange rate and is an assumed foreign exchange rate for reference only. All dollar amounts in HKD and USD are indicative and for reference only.
[8]
The Underlying Index is a net total return, free float market capitalization weighted index that provides exposure to Chinese companies that are mainly active in the field of biotechnology. A net total return index reflects the reinvestment of dividends or coupon payments, after deduction of any withholding tax (including any surcharges for special levies, if applicable).
[9]
As the Sub-Fund is newly set up, this figure is an estimate only and represents the sum of the estimated ongoing charges over a 12-month period, expressed as a percentage of the estimated average net asset value over the same period. It may be different upon actual operation of the Sub-Fund and may vary from year to year.

Back to top

Disclaimer: